Kornimate/medical-research-clean huggingface dataset:
nasal outcomes using saline irrigations after endonasal pituitary surgery

Conditions: Pituitary Tumor

Summary: this is a prospective, single-blinded, multicenter study evaluating the benefit of sinonasal irrigations following endoscopic pituitary surgery. the goal of this study is to create practice changing guidelines with objective data highlighting the importance of irrigations on postoperative outcomes for pituitary surgery.

this prospective study, coupled with the results of the recent poet study evaluating the role of antibiotics in postoperative outcomes for pituitary surgery, will guide physicians in the optimal management of patients following endoscopic pituitary surgery. the investigator group has an established record of completing multicenter studies (e.g., poet, transpher) that have influenced clinical practice guidelines, raised the profile of barrow in the pituitary and skull base community, and resulted in numerous peer-reviewed publications and awards.

Eligibility criteria:
inclusion criteria 1. adult patient undergoing endoscopic surgery for resection of pituitary tumors * nonfunctioning adenoma * acromegaly * prolactinoma * rathke's cleft cyst 2. adults \>18 and \<85 years of age 3. english speaking and able to understand the ask nasal-12 and snot-22 scales 4. free of any physical, mental, or medical condition which, in the opinion of the investigator, makes study participation inadvisable 5. planned binostril surgical approach 6. either with or without septal flap reconstruction 7. either with or without septoplasty exclusion criteria 1. active sinus infection 2. allergic rhinitis 3. asthma 4. vascular or inflammatory disease 5. history of previous sinonasal surgery 6. any subject who is unwilling or unable to sign informed consent for the study 7. pregnancy 8. incarcerated patients 9. cushing's disease 10. history of chronic sinusitis 11. extended approaches to the skull base 12. active sinusitis 13. nasal polyps 14. concurrent antibiotics for another indication (i.e., urinary tract infection) 15. immunodeficiency 16. history of radiation to the skull base
brain computer interface for communication in icu: a feasibility study

Conditions: Tetraplegia; Guillain-Barre Syndrome

Summary: the main objective of this study is to evaluate the usability of a system to assist verbal communication based on bci system using the p300 wave in patients with tetraplegia who can no longer communicate because of severe engine damage (tetraplegia) and respiratory damage requiring invasive mechanical ventilation (intubation or tracheostomy) preventing verbal communication.


Eligibility criteria:
inclusion criteria: * admitted in the icu * quadriplegic and requiring mechanical ventilation (tracheostomy) 24/24h exclusion criteria: * acute respiratory failure. * visual disorder * cognitive disorder * illiterate patient * mother tongue other than french

Keywords: brain computer interface p3speller p300 event related potential tetraplegia guillain barre syndrome feasibility speed of spelling accuracy
safety, tolerability and efficacy study of the new medication ask8007 to treat patients with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to investigate the safety and tolerability of the new medication ask8007, and to study whether it has a beneficial effect on joint inflammation in patients with rheumatoid arthritis.


Eligibility criteria:
inclusion criteria: * meet the american rheumatism association (ara) 1987 revised criteria for the classification of ra (also referred to as the american college of rheumatology \[acr\] criteria); * being treated with an adequate dose (to the discretion of the local physicians) of either mtx or leflunomide (lef)or sulfasalazine (ss2) for at least 4 months prior to baseline of which the last 6 weeks before baseline were at a stable dose; * have active poly-arthritis (i.e. active rheumatoid arthritis as defined in detail in the protocol) exclusion criteria: * have been treated with any registered or non-registered investigational drug in the context of a clinical intervention study during the last 3 months before baseline; * have been treated with tnfα-blockers within a certain period of time (defined for each medication) before baseline; * have been treated with any dmard other than mtx, lef or ss2 during the last month before baseline; * documented evidence for the presence of clinically severe, unstable, or uncontrollable renal, hepatic, respiratory, hematological, genitourinary, cardiovascular, endocrine, neurological, psychiatric, or other medical illness which would, in the opinion of the investigator, put the patient at safety risk or mask measures of efficacy.

Keywords: rheumatoid arthritis randomized control trial treatment outcomes monoclonal antibody
to study the effect of single infusions of amphotericin b lipid preparations in treatment of patients of kala azar

Conditions: Leishmaniasis, Visceral

Summary: the purpose of this study is to determine whether a single bolus of dose of amphoterin b lipid emulsion (amphomul) is as efficacious and safe compared to a single dose liposomal amphotericin b in treating patients with indian visceral leishmaniasis (kala azar).

visceral leishmaniasis, which is progressive and fatal if not treated, is an insidious, chronic disease that is characterized by irregular fever, anorexia, weight loss, cough, gross enlargement of the spleen and liver, mild anemia and emaciation. this may be preceded by rigors and vomiting. if untreated, kala-azar, which is the most severe form of leishmaniasis, has a mortality rate of nearly 100%. the goal of the project is to establish that a single dose of amphomul® can be used to achieve a definitive cure for visceral leishmaniasis leading to a short course therapy. the project will also seek to establish that amphomul ® is safe, at least as effective and more affordable than current treatment, and is without the risk of drug resistance. the trial is a prospective, multicentric, randomized, two arm, open label phase iii study to assess efficacy and safety of infusion of amphomul® (amphotericin b emulsion) as compared to liposomal amphotericin b in patients of visceral leishmaniasis (kala azar)who are either treatment naive or treatment resistant to other antileishmanial drugs.

Eligibility criteria:
inclusion criteria: * male or female patients aged between 5 to 65 years (both inclusive). * clinical signs and symptoms of visceral leishmaniasis (fever of over 2 weeks duration and splenomegaly) * presence of amastigotes (leishmania-donovani bodies) at prescreening detected by rk39 dipstick test with confirmation by splenic or bone marrow aspirate smear examination. * non-pregnant, non-lactating females of age ≥5 years, and woman of childbearing potential who are willing to use acceptable methods of contraception * negative urine pregnancy test (upt) in all women exclusion criteria: * patients with past history of treatment with amphotericin b or any other drug for visceral leishmaniasis within 30 days prior to screening. * patients positive for hiv, hcv and hbsag infection, immunocompromised patients (through history). * concurrent diabetes, tuberculosis or bacterial pneumonia or any other infectious or major psychiatric disease. * pregnant or nursing women * patients receiving any of the medications prohibited by the study protocol. * simultaneous participation in another trial or received any ip \<30 days prior to enrolment.

Keywords: black fever kala-azar amphotericin b lipid emulsion liposomal amphotericin b
pilot trial of contingency management for long-term cannabis abstinence

Conditions: Cannabis Use; Adolescent Behavior

Summary: this study is a critically important first-of-its-kind investigation of the potential research utility of using contingency management to examine long-term changes in cannabis use with six months of abstinence. these pilot data will inform a later trial which will focus on testing the longitudinal relationships between adolescent cognition and cannabis use, questions of high and growing public health significance given adolescents' increased access to cannabis with legalization.


Eligibility criteria:
inclusion criteria: * male and female adolescents actively enrolled in a middle or high school in the boston area who are between the ages of 13 and 19 (inclusive); * average use of cannabis at least 3 times per week during the 3 months prior to study enrollment; * cannabis use reported within 7 days of study enrollment; * no immediate plan to discontinue cannabis use; * have a parent or legal guardian who is competent and willing to provide written informed consent for the active study phase (if under the age of 18); * competent and willing to provide written informed assent for the active study phase (if under the age of 18); * competent and willing to provide written informed consent (if age 18 or older); * able to communicate in english language; * have a parent/guardian who can communicate in english language; * able to commit to 27 study visits in approximately 6 months; * able to safely participate in the protocol and appropriate for outpatient level of care, in the opinion of the investigator. exclusion criteria: - any severe developmental delays (including, but not limited to, autism spectrum disorder, intellectual disability, and down syndrome).
evaluation of serum ages levels in patients with endometriosis

Conditions: Endometriosis

Summary: serum ages (advanced glycation end products) levels of endometriosis patients are compared with a group of healthy volunteers of the same age.

serum ages (advanced glycation end products) levels are compared with 45 endometriosis patients and 45 healthy volunteers of the same age. the energy metabolism of the endometriosis group and its possible relationship with the endometriosis stage will be compared since ages (advanced glycation end products) gives information about the energy metabolism of the people.

Eligibility criteria:
inclusion criteria: * diagnosed with endometriosis (surgery or ultrasound) * women without endometriosis exclusion criteria: * women without endometriosis women who are only suspected endometriosis

Keywords: ages (advanced glycation end products)
turkish version of the upper limb hypermobility assessment tool

Conditions: Hypermobility, Joint

Summary: hypermobility is more than normal joint laxity, mobility, and range of motion. it is characterized by increased laxity and fragility of connective tissues. symptoms from hypermobility can begin at any age and affect women more than men. people are at higher risk than other people. it is stated that hypermobility is an important factor in orthopedic injuries and diseases. individuals with hypermobility have more frequent orthopedic complaints and the problems are usually idiopathic and chronic. studies have reported that proprioception and musculoskeletal reflex function may be affected independently of symptoms in hypermobile individuals. therefore, evaluating hypermobility is very important in preventing hypermobility-related problems and injuries and developing appropriate treatment methods. although the beighton score is the most commonly used scoring method to determine hypermobility, it may be insufficient to determine hypermobility of the upper extremities. the upper limb hypermobility assessment tool (ulhat) has been reported to be one of the most appropriate scoring methods for assessing upper extremity hypermobility in the literature. the aim of this study is to adapt ulhat to turkish and measure its validity and reliability.


Eligibility criteria:
inclusion criteria: * healthy volunteers * aged between 18 to 35 exclusion criteria: * using assistive devices or orthoses for the upper extremity * surgery history of the upper extremity * pain located on the upper extremity in the last 6 months * previous trauma that might restrict normal range of motion. * having degenerative or inflamatuar disease
comprehensive geriatric assessment (tests) for bladder cancer participants undergoing radical cystectomy

Conditions: Bladder Cancer

Summary: this study focuses on providing an educational program for people/participants with bladder cancer who plan to have a cystectomy (surgery) as part of their standard care. participants in this study will watch videos designed to teach them strategies to help lower their risk of experiencing negative side effects (such as mobility problems, issues with taking medication, and poor quality of life) before and after they have surgery. they will also be asked to fill out questionnaires.

this study focuses on providing an educational program for participants/people with bladder cancer who plan to have a cystectomy (surgery) as part of their standard care. participants in this study will watch videos designed to teach them strategies to help lower their risk of experiencing negative side effects (such as mobility problems, issues with taking medication, and poor quality of life) before and after they have surgery. the goal of this study is to educate people with bladder cancer and ask them to also fill out questionnaires about the education program and if they used any of the strategies that learn during the study. participants in this study will be divided into two different study groups (one group that watches educational videos before surgery and one group that watches educational videos before surgery and also receives geriatric services and follow up visits after surgery). each participant will be randomized (randomly assigned) to one of two study groups. that means that there is a 50/50 chance (like flipping a coin) that each participant will end up in either group.

Eligibility criteria:
inclusion criteria * participants capable of giving consent * participants undergoing radical cystectomy (both for curative and palliative intent) for bladder cancer diagnosed by tissue pathology with urinary diversion at the university of chicago * participants undergoing neoadjuvant chemotherapy will be included * participants will be included regardless of gender, race or ethnicity * participants greater than or equal to 65 years of age exclusion criteria * radical cystectomy for non-oncologic indications * palliative cystectomy for cancers other than bladder cancer (i.e. prostate, rectal, cervical)

Keywords: cystectomy radical cystectomy
rosiglitazone (avandia®) treatment in hiv: its effect on blood vessels

Conditions: Atherosclerosis; HIV Infections

Summary: this trial will study the effect of rosiglitazone on the progression of atherosclerosis (hardening of blood vessels) through improvements of the sugar and fat metabolism (body buildup, breakdown and excretion of sugar and fat). participants will be randomly assigned to one of two groups: the first group will receive 8 mg of the study drug and the second group will be given a placebo, though neither group will know which formulation they are receiving. the study will follow both groups for one year, during which it will measure changes in blood vessel composition and activity, sugar metabolism, concentration of blood fat, and body fat distribution. this single-site study aims to enroll 50 participants.


Eligibility criteria:
inclusion criteria: * hiv-positive * between 30 and 70 years of age * elevated blood levels of fat * on two or more anti-hiv drugs for at least12 months in a row and unlikely to change anti-hiv therapy during the study * on stable regimen for at least 6 months for women taking oral contraceptive agents or hormone replacement * on a stable regimen for at least 6 months for men on testosterone replacement * if taking nevirapine, on therapy for at least 3 months with stable liver function tests exclusion criteria: * pregnancy and breastfeeding * poorly controlled diabetes * uncontrolled hypertension or clinical evidence of heart failure * any serious medical conditions, including an active aids-defining condition, pancreatitis, or hepatitis within 6 months prior to the study * laboratory abnormalities (see investigator) * on lipid lowering agents, insulin, anabolic steroids (except for testosterone at replacement doses), oral corticosteroids at greater than replacement doses, or growth hormones * history of liver reaction or severe edema associated with current thiazolidinedione * history of hypersensitivity to thiazolidinedione

Keywords: treatment experienced hiv metabolic syndrome atherosclerosis in hiv
dissection of the gastrointestinal-mediated glucose disposal and incretin defect in patients with type 2 diabetes

Conditions: Type 2 Diabetes

Summary: in patients with type 2 diabetes, the incretin effect is markedly reduced contributing to the relative insulin deficiency that characterizes these patients. this defect is believed to be due to a decreased effect of glp-1 and an almost ceased effect of gip. nevertheless, the impact of the defect on glucose tolerance is not fully understood. the so-called gastrointestinal-mediated glucose disposal (gigd) is a measure of glucose handling, which includes the incretin effect, but also other factors affecting glucose disposal (e.g. glucagon secretion). interestingly, patients with type 2 diabetes exhibit elevated plasma glucagon levels in the fasting state, and glucagon concentrations fail to decrease appropriately and may even increase in response to ingestion of glucose and show exaggerated increases after a mixed meal. with the current project the investigators wish to elucidate how this paradoxical glucagon response observed in patients with type 2 diabetes affects the gigd, the incretin effect and postprandial glucose excursions. ten patients with type 2 diabetes and 10 healthy matched control subjects will be enrolled in this randomised, placebo-controlled, double-blinded study. the aim is to examine the effect of a glucagon receptor antagonist (gra) on gastrointestinal-mediated glucose disposal (gigd), incretin effect and postprandial glucose excursions in patients with type 2 diabetes and healthy controls. participants will attend two oral glucose tolerance tests (ogtt), two isoglycaemic iv glucose infusion (iigi) and two standardised liquid meals.


Eligibility criteria:
inclusion criteria: patients with type 2 diabetes * caucasians above 35 years of age with diet or metformin treated type 2 diabetes for at least 3 month (diagnosed according to the criteria of the world health organization (who) * normal haemoglobin * informed consent healthy subjects * normal fasting plasma glucose (fpg) \<6.1 mmol/l and hba1c \<42 mmol/mol (6.0%) * normal haemoglobin * age above 35 years * informed consent exclusion criteria: patients with type 2 diabetes * inflammatory bowel disease * intestinal resections * nephropathy (serum creatinine above normal range and/or albuminuria) * liver disease (serum alanine aminotransferase (alat) and/or serum aspartate aminotransferase (asat) \>2×normal values) * treatment with medicine that cannot be paused for 12 hours * pregnancy and/or breastfeeding * family history of pancreatic islet tumours * age above 80 years healthy subjects * diabetes or prediabetes with reduced glucose tolerance: fpg \>6.0 mmol/l and/or hba1c \>42 mmol/mol * first degree relatives with type 2 diabetes * inflammatory bowel disease * intestinal resections * treatment with medicine that cannot be paused for 12 hours * pregnancy and/or breastfeeding * age above 80 years
value of laboratory biomarkers in prediction of outcome in septic patients

Conditions: Sepsis

Summary: sepsis is defined as a dysregulated host response to infection . despite ongoing efforts, both the incidence and mortality of sepsis have demonstrated limited reductions over the past years,there are several biomarkers that have already been studied for the early diagnosis of sepsis. some of these markers can be used in risk prediction and monitoring the outcome of sepsis . some of these markers as procalcitonin and cd14, are costly and not feasible options for low- and middle-income countries . while other biomarkers are feasible and accessible to be evaluated as triglyceride\\glucose index (tyg) , relative distributive width of red blood corpuscles to albumin ratio (rar), c-reactive protein,neutrophile \\lympocyte ratio and serum lactate levels .

sepsis is defined as a dysregulated host response to infection . despite ongoing efforts, both the incidence and mortality of sepsis have demonstrated limited reductions over the past years, there are several biomarkers that have already been studied for the early diagnosis of sepsis. some of these markers can be used in risk prediction and monitoring the outcome of sepsis . triglyceride-glucose (tyg) index has emerged as a surrogate marker of insulin resistance which is often prevalent in patients with sepsis. red blood cell distribution width (rdw) is a common clinical hematology indicator that reflects the heterogeneity of red blood cell size. as a simple and inexpensive parameter, rdw has been successfully used to predict the prognosis of many diseases, including cardiovascular disease, kidney disease, diabetes mellitus, and liver disease . recent studies have also shown that rdw is significantly associated with the mortality of sepsis. rdw to albumin ratio was evaluated as a novel and simple biomarker of inflammation. -c-reactive protein (crp) is a sensitive indicator of the body, reflecting damage and infection . serum albumin level drops significantly in the acute stage of infection (16). crp/alb ratio (car) could be a marker to predict mortality in sepsis. the neutrophil-lymphocyte ratio (nlr) is an-inflammatory biomarker that can be used as an indicator of systemic inflammation. it is a simple that does not add costs to complete blood count laboratory examinations, which are performed routinely in hospitals. it was tested as a guide for the prognosis of various diseases, such as cancer, community pneumonia and sepsis. although these various biomarkers that have been proposed, no single clinical or biological indicator of sepsis has gained general acceptance . and to our knowledge, no previous study compared between these indicators in prediction of sepsis outcome or determined the clinical significance of combination of multiple biomarkers in prognosis of sepsis .

Eligibility criteria:
inclusion criteria: - patients whom will be diagnosed with sepsis exclusion criteria: * patients diagnosed by hematological disease * patients refused to participate in the research * patients less than 18 years
evaluation of treatment for leukoderma by cellular level resolution full-field optical coherence tomography

Conditions: Leukoderma

Summary: oct is an optical technology that emerged as a non-invasive skin imaging for the skin. in this protocol, the investigators plan to study the optical imaging features of leukoderma. an estimated 65 subjects will be included in this trial. this is an observational, non-randomised, non-controlled, prospective cohort study to observe the feasibility of in vivo oct as a image tool in the diagnosis of leukoderma. use of the device will not affect the clinical management of the subjects. scientific aim: to evaluate the feasibility apollovue s100 image system as a tool in the differential diagnosis of leukoderma..


Eligibility criteria:
inclusion criteria: 1. age ≧ 20 2. subject with at least one leukoderma lesion 3. willing to participate in the trial with informed consent exclusion criteria: 1. age \< 20 2. pregnant woman or woman wishing to be pregnant during the study, or during breastfeeding period 3. the investigators consider inappropriate to participate in the trial. 4. open wound lesion.

Keywords: optical coherence tomography (oct) dermatology full-field oct non-invasive image system leukoderma